Older adults with IBD (≥60) were once thought to be at lower risk of developing antibodies to infliximab; HOWEVER, an analysis of over 22K Anser® IFX results showed this patient population was: • More likely to develop IFX antibodies -AND- • Less likely to receive escalated dosing Precision-guided dosing, with PredictrPK® IFX, may afford HCPs actionable data to expediently and precisely optimize care, reducing the likelihood of antibody formation and thus support drug durability and sustained therapeutic response for this growing patient population. https://lnkd.in/ep6xhKnp
Prometheus Laboratories Inc.
Biotechnology
San Diego, CA 7,831 followers
Empowering Precision
About us
At Prometheus Laboratories Inc., we enable unique health solutions with novel diagnostics. As a leader of precision healthcare in gastroenterology, we develop and bring to market diagnostic tests that help physicians provide the highest level of patient care. Our commitment to innovation positions us for future growth and lays the foundation for expansion into new areas. Every day our people and products earn the trust of patients and their families.
- Website
-
http://www.prometheuslabs.com
External link for Prometheus Laboratories Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- San Diego, CA
- Type
- Privately Held
- Specialties
- Diagnostics, Gastroenterology, Biotechnology, and Clinical Laboratory
Locations
-
Primary
9410 Carroll Park Dr
San Diego, CA 92121, US
Employees at Prometheus Laboratories Inc.
Updates
-
#ICYMI @ #DDW2024 | Low clearance and high #IFX/#ADA levels play an important role in #Crohns outcomes. Routinely assessing both may be critical for personalized dosing, optimized therapy & improved patient outcomes in IBD. #IBD #GITwitter #IBDTwitter bit.ly/PLIatDDW2024
-
#ICYMI @ #DDW2024 | Real-world evidence supporting PredictrPK® #ADA. Optimized dosing and #adalimumab clearance are key to mitigating the risk of active disease and therapy discontinuation. #IBD #GITwitter #IBDTwitter bit.ly/PLIatDDW2024
-
Last year at the Crohn's & Colitis Foundation Take Steps event, we were proud to win the title of top fundraiser. Help us stay #1! Raise #IBD awareness and join us for Take Steps 2024 @ Liberty Station, San Diego! We hope to see you on June 2nd. https://lnkd.in/gfCDYUFC
-
We want to thank everyone that came by to discuss how precision-guided dosing is reshaping #IBD treatment w/ predictions that empower you to control the trajectory of #IFX/#ADA levels. See you next year in San Diego! #Crohns #Colitis #IBDTwitter #DDW2024 bit.ly/PLIatDDW2024
-
So much of #DDW2024 focused on #PrecisionMed & our team at booth 2028 is ready to answer your questions about how precision-guided #IFX/#ADA dosing supports evidence-based optimization for durable & sustained response #IBD #GITwitter #IBDTwitter bit.ly/PLIatDDW2024
-
Prometheus Laboratories Inc. reposted this
Scientific advancement is just the first step to bring new, more effective treatment solutions that are needed to improve patient care. Once commercially available, it’s vital to work with payers to enable access to new innovations as quickly as possible. We’ve just announced another major step forward in securing coverage and availability of our novel precision-guiding PredictrPK clinical tests that help in the goal of more effectively treating patients with chronic diseases like #IBD.
We are excited to announce the execution of a provider agreement with three large regional health plans to facilitate access to PredictrPK®, precision-guided biologic testing, and other Prometheus testing services to participating health plans and their respective members. This agreement makes our testing services available within these three large regional health plans, representing five million members. Precision-guided biologic dosing to assess the right dose and right interval for each individual patient offers significant potential to reduce overall cost of care and waste related to failed biologic therapy and we are pleased to collaborate with forward-thinking health plans to advance value-driven care. https://lnkd.in/g8vE5uFT
-
On Sunday at DDW®, nine posters focusing on the clinical validity, utility, and health economic impact of precision-guided care in IBD were unveiled. The presentations not only tapped into one of the world's largest biorepositories of well-characterized IBD patient samples but also curated data from over 80 clinical study cohorts. The data presented illustrates how our use of predictive analytics is ushering in a new era of individualized, actionable testing solutions for IBD and demonstrates how precision-guided care is enabling evidence-based and more cost-effective treatment. https://lnkd.in/gmqkXg48 #Biorepository #ChronicIllness #ClinicalResearch #CostEffectiveCare #CrohnsDisease #DDW2024 #DiseaseAwareness #EvidenceBasedMedicine #Gastroenterology #GIHealth #GlobalHealth #HealthcareAdvocacy #HealthcareAwareness #HealthcareCommunity #HealthcareEducation #HealthcareEquality #HealthcareInnovation #HealthcareProgress #HealthEconomics #HEOR #IBDAwareness #IBDResearch #IndividualizedCare #InflammatoryBowelDisease #MedicalAdvancements #MedicalInnovation #MedicalResearch #PatientAdvocacy #PatientSupport #PrecisionMedicine #PredictiveAnalytics #TreatmentOptions #UlcerativeColitis
-
Sunday #DDW2024 poster: Impact of intrinsic #antiTNF clearance & #genetics on likelihood of response. Evidence-based care for informed biologic management. Learn more: poster Su1815 #PrecisionMed #GITwitter #IBDTwitter bit.ly/PLIatDDW2024
-
Sunday #DDW2024 poster: Long-term hospitalization & surgery rates in #IFX-treated #IBD patients undergoing regular therapeutic drug monitoring vs a no #TDM control group. See poster Su1799 or visit booth 2028 to learn more. @lynx_md #GITwitter #HEOR bit.ly/PLIatDDW2024